title: Simultaneous determination and pharmacokinetic study of roxithromycin and ambroxol hydrochloride in human plasma by LC-MS/MS.
abstract: BACKGROUND
  Although roxithromycin and ambroxol HCl were often administered concomitantly for the treatment of respiratory infections, the pharmacokinetic interactions between them have not been reported. We investigated the interactions between these drugs in health male Chinese volunteers by LC-MS/MS in human plasma.
  
  
  METHODS
  The pharmacokinetics were studied in 12 healthy male Chinese volunteers after an overnight fast by a single oral dose, 4-way crossover design with a period of 7-day washout. Each subjects was randomized to receive a single oral dose of 1 compound roxithromycin (150 mg) and ambroxol HCl (30 mg) dispersible tablet (test formulation, treatment A), one 150 mg roxithromycin dispersible tablet together with one 30 mg ambroxol HCl tablet (combined reference formulations, treatment B), one 150 mg roxithromycin dispersible tablet (reference formulation I, treatment C), or one 30 mg ambroxol HCl tablet (reference formulation II, treatment D) with 250 ml of water. Venous blood was collected at pre-dose (0 h) and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72 h after dosing. The plasma concentrations of roxithromycin and ambroxol HCl were simultaneously determined by using a validated internal standard LC-MS/MS method.
  
  
  RESULTS
  No significant differences were observed for the major pharmacokinetic parameters such as C(max), T(max), t(1/2) and AUC of both roxithromycin and ambroxol HCl between different treatments.
  
  
  CONCLUSIONS
  The pharmacokinetics of both roxithromycin and ambroxol HCl are not affected by their concomitant oral administration. Therefore, there are no obvious pharmacokinetic interactions between roxithromycin and ambroxol HCl after oral administration. Roxithromycin and ambroxol HCl dispersible tablets were bioequivalent with reference to the roxithromycin dispersible tablets and ambroxol HCl tablets in combination usage.
authors.affiliation: Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, PR China. hangtj@cpu.edu.cn
authors.forename: Tai-Jun
authors.initials: TJ
authors.lastname: Hang
authors.forename: Meng
authors.initials: M
authors.lastname: Zhang
authors.forename: Min
authors.initials: M
authors.lastname: Song
authors.forename: Jian-Ping
authors.initials: JP
authors.lastname: Shen
authors.forename: Yin-di
authors.initials: YD
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000551:Ambroxol / Q000097:blood / Q000493:pharmacokinetics*; D000900:Anti-Bacterial Agents / Q000097:blood / Q000494:pharmacology*; D002853:Chromatography, Liquid / Q000379:methods; D018592:Cross-Over Studies; D004347:Drug Interactions; D005100:Expectorants / Q000032:analysis / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D015575:Roxithromycin / Q000097:blood / Q000493:pharmacokinetics*; D053719:Tandem Mass Spectrometry / Q000379:methods*
chemical_list: D000900:Anti-Bacterial Agents; D005100:Expectorants; D000551:Ambroxol; D015575:Roxithromycin